The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Validation, 2014Targeting Internalization and Aggregation of Alpha-synuclein Proteopathic Seeds with Glycosaminoglycan Interacting Small Molecules (GISMO)
Objective/Rationale:
Evidence points to key roles for alpha-synuclein and cell-surface glycosaminoglycans (GAGs) — a type of carbohydrate molecules — in the onset of neurodegenerative... -
Access to Data and Biospecimens, 2014Analysis of Circulating Brain-Enriched microRNA as Biomarkers for Parkinson’s Disease
Study Rationale:
Early detection of neurodegenerative diseases can lead to more effective therapeutic intervention. DiamiR proposes a diagnostic approach based on analysis of... -
Research Grant, 2014Increasing Glucocerebrosidase Activity as a Therapeutic Strategy
Objective/Rationale:
Mutations in GBA1, the gene encoding the protein glucocerebrosidase, represent a common genetic risk factor for developing Parkinson disease (PD). PD patients with and... -
Therapeutic Pipeline Program, 2014Development of a mGluR4 Therapeutic for Parkinson's Disease
Study Rationale:
One of the major objectives for the development of new treatments for Parkinson’s disease is to find alternatives to the stimulation of the dopaminergic system through levodopa and... -
Target Validation, 2014Role of Kinase Fyn in Levodopa-induced Dyskinesia
Study Rationale:
Levodopa frequently induces dyskinesia, an abnormal involuntary movement. In our laboratory we study how and where the prolonged use of levodopa modifies the brain of pre-clinical... -
Rapid Response Innovation Awards, 2014Inhibition of Retinoic Acid Metabolism for the Treatment of Parkinson’s Disease
Study Rationale:
Several lines of evidence point to the therapeutic potential of Retinoic acid (RA), a metabolite of vitamin A, in the treatment of Parkinson’s disease. For example, RA treatment...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.